- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05035810
A Pragmatic Trial to Determine the Benefit of Behaviorally Enhanced Exercise Incentives and Corticosteroid Injections in Osteoarthritis of the Knee Marching On for Veterans With Osteoarthritis of the Knee (MOVE-OK)
A Pragmatic Trial to Determine the Benefit of Behaviorally Enhanced Exercise Incentives and Corticosteroid Injections in Osteoarthritis of the Knee
Study Overview
Status
Conditions
Detailed Description
Knee osteoarthritis (KOA) is one of the most prevalent and disabling conditions among Veterans and accounts for high morbidity and high costs for the VA. Management of KOA is challenging as there are few consistently effective treatments other than joint replacement. Importantly, chronic reductions in physical activity in patients with KOA may worsen pain, physical function, and exacerbate the metabolic consequences of obesity. Moreover, the greater mortality observed in symptomatic knee OA populations is likely mediated through its effect on physical activity. The current proposal aims to derive preliminary data to support a large pragmatic trial testing the impact of interventions geared towards improving physical activity and function in KOA patients.
Promoting physical activity has been shown to be helpful in reducing pain and improving function in KOA and other groups. However, promoting behavioral change in the arthritis population is a significant challenge. The group has shown that social incentives [and gamification] derived from concepts from the field of behavioral economics to promote behavioral change and increase physical activity can be both practical and effective in other settings. The investigators' group is studying incentives in patients with inflammatory arthritis with the goal of addressing fatigue, pain, and deficits in physical function. The incentivization of physical activity using this approach represents a novel intervention for the managing symptoms of KOA and to improving overall health.
Analgesic therapies can help KOA patients participate in exercise therapy. However, whether corticosteroid injections, a commonly used medical therapy for KOA pain, has a positive impact of physical activity is unknown and is an additional important question addressed by the current proposal. Despite widespread use, definitive data demonstrating a consistent benefit of corticosteroids are lacking. A large randomized trial recently tested the effects of repeated corticosteroids injections every 3 months for a period of 2 years on patient reported pain as well as progression of disease measured by magnetic resonance imaging (MRI). This study demonstrated no improvement in pain compared to saline injections. In addition, a small but statistically significant decline in cartilage thickness on MRI was observed, raising a concern for side effects. These recent data might suggest that corticosteroid injections result in more harm than good, and may discourage providers from performing this intervention. However, there are critical weaknesses to this study. Pain and function were only assessed at 3-month intervals, while previous trials have suggested that peak benefit is expected at 4-8 weeks. Moreover, the clinical and biologic significance decrease in cartilage thickness is unclear.
The investigators propose to fill these important knowledge gaps with an innovative and efficient pragmatic clinical trial with a factorial and crossover design. A large and definitive practical trial would lead to better understanding of the clinical effectiveness of these interventions, the meaningfulness of their combined impact, and the subgroups that are most likely to derive benefit. This clinical trial will leverage unique resources available through the Penn Center for Innovation to better capture important patient-reported outcomes in real-time through a web-based platform. The study will also test the feasibility of a crossover and factorial design to improve efficiency and reduce confounding. Each patient will receive each intervention (saline, corticosteroids) in random order over 1 year. A factorial design will be employed and will randomize participants to receive social incentives with gamification to promote increases in their physical activity. To accomplish these aims, the investigators will utilize innovative mobile applications for smart phones and wearable activity trackers through the Way-to-Health platform and assess, in real time, the impact of the intervention on patient-reported function and pain as well as physical activity. The technology will allow for the recording of outcomes as they occur, between clinic visits, thereby avoiding information bias due to poor recall. It will also provide real-time assessment of symptoms, providing granular assessments of response over time.
Aim 1: To determine whether an incentive based on behaviorally-enhanced gamification can improve physical activity among patients with KOA and reduce self-reported pain and disability. The intervention will result in sustained improvements in average daily step counts over 10 months.
Aim 2: To determine if corticosteroid injections can reduce pain and disability in patients with KOA when compared to lidocaine only. Participants will report improvements in self-reported pain and disability, and improvements in quality of life.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Joshua F Baker, MD MSCE
- Phone Number: (215) 823-5800
- Email: Joshua.Baker@va.gov
Study Contact Backup
- Name: William T Leach, MA BS
- Phone Number: 204630 (215) 823-4630
- Email: William.Leach@va.gov
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20422
- Recruiting
- Washington DC VA Medical Center, Washington, DC
-
Contact:
- Mercedes Quinones, MD
- Phone Number: 202-745-8000
- Email: Mercedes.Quinones@va.gov
-
-
Nebraska
-
Omaha, Nebraska, United States, 68105-1873
- Recruiting
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
-
Contact:
- Bryant England, MD
- Phone Number: 402-888-6728
- Email: Bryant.England@va.gov
-
Contact:
- Bridget Kramer
- Email: bridget.kramer@unmc.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104-4551
- Recruiting
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
-
Contact:
- Joshua F Baker, MD MSCE
- Phone Number: 215-823-5800
- Email: Joshua.Baker@va.gov
-
Principal Investigator:
- Joshua F. Baker, MD MSCE
-
-
Washington
-
Seattle, Washington, United States, 98108
- Recruiting
- VA Puget Sound Health Care System Seattle Division, Seattle, WA
-
Contact:
- Katherine D Wyshan, MD
- Phone Number: 206-764-2251
- Email: Katherine.Wysham@va.gov
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Veterans in VA Rheumatology or Orthopedic clinics
- Chronic knee osteoarthritis
- Indication for joint injection
- Previous joint injections for palliation
- Patient expresses interest in increasing their physical activity
- Patient is able to walk 1/2 mile per day
Exclusion Criteria:
- Intra-articular hardware or other contraindication to joint injection
- Lack of smart phone
- Acute exacerbation of osteoarthritis or knee pain
- Comorbid condition that precludes safe exercise
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Social Incentives and Gamification, Corticosteroid AB
Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals. The participants will receive injections in A-B order (corticosteroids, then lidocaine only) |
The intervention will provide social incentives and gamification to promote physical activity.
The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design.
These participants will receive the medication in A-B order.
|
Active Comparator: No Incentive, Corticosteroid AB
Participants will only receive reminders to sync their activity monitor. The participants will receive injections in A-B order (corticosteroids, then lidocaine only) |
No social incentive will be applied
The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design.
These participants will receive the medication in A-B order.
|
Experimental: Social Incentives and Gamification, Corticosteroid BA
Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals. The participants will receive injections in B-A order (lidocaine only, then corticosteroids) |
The intervention will provide social incentives and gamification to promote physical activity.
The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design.
These participants will receive the medication in B-A order.
|
Active Comparator: No Incentive, Corticosteroid BA
Participants will only receive reminders to sync their activity monitor. The participants will receive injections in B-A order (lidocaine only, then corticosteroids) |
No social incentive will be applied
The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design.
These participants will receive the medication in B-A order.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent change from baseline in weekly average steps per day
Time Frame: Measured weekly over 10 months (for exercise intervention)
|
Steps measured by a wearable activity monitor
|
Measured weekly over 10 months (for exercise intervention)
|
Change in Knee Injury and Osteoarthritis Outcome Score (KOOS)
Time Frame: Measured bi-weekly over 3 months (for injection intervention)
|
KOOS assessed by survey at 2 week intervals.
KOOS scores range from 0 to 100 with 0 representing worse knee problems and 100 representing no knee problems.
|
Measured bi-weekly over 3 months (for injection intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in PROMIS pain intensity score
Time Frame: Measured bi-weekly over 3-10 months (3 for injection intervention and 10 for exercise intervention)
|
Assessed by survey at 2 week intervals.
Scores range from 3-15 and are converted to T-Scores.
A high score represents greater pain.
|
Measured bi-weekly over 3-10 months (3 for injection intervention and 10 for exercise intervention)
|
Change in PROMIS Fatigue
Time Frame: Measured every 4 weeks over 3-10 months (3 for injection intervention and 10 for exercise intervention)
|
Assessed by survey at 4 week intervals
|
Measured every 4 weeks over 3-10 months (3 for injection intervention and 10 for exercise intervention)
|
Change in Knee Injury and Osteoarthritis Outcomes Score (KOOS)
Time Frame: Measured bi-weekly over 10 months (for exercise intervention)
|
KOOS assessed by survey at 2 week intervals.
KOOS scores range from 0 to 100 with 0 representing worse knee problems and 100 representing no knee problems.
|
Measured bi-weekly over 10 months (for exercise intervention)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Joshua F. Baker, MD MSCE, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- F3644-R
- RX003644-01A1 (Other Grant/Funding Number: VA RR&D)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis of the Knee
-
Taiwan Liposome CompanyCompletedOSTEOARTHRITIS OF THE KNEETaiwan, United States
-
University Hospital, GhentCompletedOsteoarthritis of the Knee JointBelgium
-
Bone Therapeutics S.ANordic Bioscience A/SCompletedSymptomatic Osteoarthritis of the KneeDenmark, Belgium, United Kingdom, Czechia, Hong Kong, Moldova, Republic of, Poland
-
Rush University Medical CenterWithdrawnSymptomatic Osteoarthritis of the Knee
-
Region SkaneRecruitingOsteoarthritis of the Knee or HipSweden
-
UMC UtrechtCompletedMedial Compartment Osteoarthritis of the KneeNetherlands
-
Massachusetts General HospitalGöteborg University; Seoul National University Hospital; Ulsan University Hospital and other collaboratorsUnknownOsteoarthritis of the Knee | Traumatic Arthritis of the KneeUnited States
-
Ampio Pharmaceuticals. Inc.TerminatedSevere Osteoarthritis of the KneeUnited States
-
Ampio Pharmaceuticals. Inc.TerminatedSevere Osteoarthritis of the KneeUnited States
-
Hospital General de Jerez de la FronteraZiekenhuis Oost-LimburgCompletedPainful Osteoarthritis of the KneeSpain
Clinical Trials on Social Incentives and Gamification to Promote Exercise
-
Abramson Cancer Center at Penn MedicineNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingPhysical ActivityUnited States
-
University of PennsylvaniaCompleted
-
VA Office of Research and DevelopmentCompletedOsteoarthritis of the KneeUnited States
-
University of PennsylvaniaCompletedPeripheral Artery DiseaseUnited States
-
University Rovira i VirgiliEuropean Commission; Hospital Universitari Sant Joan de Reus; Centro Tecnológico... and other collaboratorsCompletedObesity | Life StyleSpain
-
The University of Hong KongUniversity Grants Committee, Hong KongRecruitingDiabetes Mellitus, Type 2Hong Kong
-
Abramson Cancer Center at Penn MedicineAmerican Heart Association; City of Hope National Medical CenterRecruitingCardiovascular Diseases | Breast Cancer | Prostate Cancer | Physical InactivityUnited States
-
The University of Hong KongUniversity Grants Committee, Hong KongCompletedDiabetes Mellitus, Type 2Hong Kong
-
University of PennsylvaniaProgressive Auto InsuranceCompletedDriving Impaired | Distracted DrivingUnited States
-
Yale UniversityUniversity of California, Berkeley; University of Connecticut; Innovations for... and other collaboratorsCompleted